Singapore markets close in 42 minutes

LLY Jan 2026 630.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
63.020.00 (0.00%)
As of 02:06PM EST. Market open.
Full screen
Previous close63.02
Open61.30
Bid0.00
Ask0.00
Strike630.00
Expiry date2026-01-16
Day's range61.30 - 63.02
Contract rangeN/A
Volume2
Open interestN/A
  • Yahoo Finance Video

    Weight loss drugs: Why state health providers should cover them

    North Carolina's state health plan will deny coverage of some GLP-1 weight loss drugs, including Novo Nordisk's (NVO) Wegovy and Ozempic, and Eli Lilly's (LLY) Mounjaro. The state claims the drugs are too expensive to cover. University of Pennsylvania Vice Provost for Global Initiatives Dr. Ezekiel Emanuel joins Yahoo Finance to discuss why he feels the drugs are cost-effective for certain patients, and offers strategies for the state to pay for the coverage. Emanuel explains how North Carolina State health officials advanced a limited view of cost-effectiveness: "If you look at the cost-effectiveness analyses of these drugs for patients who have obesity, they're cost effective. They, in fact, meet [the executive director of the health plan's] criteria, and they do a lot of good for patients who have obesity. Not only do they reduce weight, they also reduce their risk of cardiovascular disease by 20% in the first year. So, they meet his standard of cost-effectiveness. He did not actually do the calculations and examine whether they're cost-effective or not." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino

  • Yahoo Finance Video

    M&A on the horizon? Viking Therapeutics extends rally

    Shares of Viking Therapeutics (VKTX) continued surging Wednesday after the company reported positive mid-stage trial data for its experimental obesity drug. BTIG Director and Biotechnology Research Analyst Justin Zelin joins Yahoo Finance Live to discuss. Zelin notes it's been a "great run" for Viking as the stock soared over 400% on the trial results, exceeding expectations. The 13-week study showed 15% weight loss, but Zelin notes this could reach 25 to 30% "after about a year." These efficacy levels are superior to similar products developed by rivals Eli Lilly (LLY) and Novo Nordisk (NOVO). Zelin adds Viking's drug has dual benefits, exciting investors. With pharmaceuticals gaining greater investor attention lately, he sees the potential for a merger opportunity given the promising success of the company. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Angel Smith

  • Insider Monkey

    12 Best ESG Dividend Stocks to Buy According to Hedge Funds

    In this article, we discussed 12 best ESG dividend stocks according to hedge funds. You can skip our detailed analysis of ESG investing and its prospects, and go directly to read 5 Best ESG Dividend Stocks to Buy According to Hedge Funds. The concept of ESG, which stands for Environmental, Social, and Governance, was initially […]